Shorts

1:08
Reacting to the FDA Advisory Committee Verdict on RP1 in Melanoma
2 months ago
by
Vincent Ma, MD

0:42
Could GLP-1s Have Anticancer Effects?
2 months ago
by
Jess Paulus, ScD

1:04
Breaking Free From Infusion Centers With SC Myeloma Treatment
2 months ago
by
Joseph Mikhael, MD

0:35
Breakthough in Long-Term TNBC Management With KEYNOTE-522
2 months ago
by
Javier Cortés, MD, PhD

0:31
Why Standardized Oncology Care is a Global Necessity
2 months ago
by
Daniel Araujo, MD

0:42
Uncovering the Secrets of Tumor Resistance
2 months ago
by
Edgardo Santos Castillero, MD, FACP, FASCO

0:50
Is Oncology Ready for Multi-Cancer Blood Tests?
2 months ago
by
Ranjit Goudar, MD

0:50
Most Women Don't Know This Major Cancer Risk
2 months ago
by
Darren Mays, PhD, MPH

0:33
Genetic Testing Isn’t the End of the Story
2 months ago
by
Ranjit Goudar, MD

0:43
Why the VIKTORIA-1 Study Matters in Breast Cancer
2 months ago
by
Erica Stringer-Reasor, MD

0:42
The Necessary Shift From Cancer Treatment to Early Detection
2 months ago
by
Ranjit Goudar, MD

0:55
How Genetic Testing Can Save Entire Families
2 months ago
by
Ranjit Goudar, MD

0:17
Dr Singhi Busts Lung Cancer Myths
2 months ago
by
Eric Singhi, MD

0:35
Menin Inhibitors Join AML’s Targeted Therapy Revolution
2 months ago
by
Eunice Wang, MD

0:45
The Patient Has a Voice in Their Cancer Treatment Plan
3 months ago
by
Estelamari Rodriguez, MD, MPH

0:48
Is There Hope for Stage IV Lung Cancer?
3 months ago
by
Estelamari Rodriguez, MD, MPH

0:37
Why Women's Lung Cancer Symptoms Are Often Ignored
3 months ago
by
Estelamari Rodriguez, MD, MPH

0:54
Don't Be Scared to Ask Experts
3 months ago
by
Kurt Demel, MD

0:29
The 2 Types of Future Oncologists
3 months ago
by
Yan Ji, MD

1:01
Why CAR T Clinical Trials Don't Tell the Whole Story
3 months ago
by
Doris K. Hansen, MD

0:47
Golcadomide’s Unique CELMoD Mechanism Explained
3 months ago
by
Daniel Morillo, MD

0:40
Ziftomenib Moves Toward Phase 3 in Frontline AML
3 months ago
by
Amer Zeidan, MBBS

0:36
Ziftomenib Combo Shows Acceptable Induction Safety in AML
3 months ago
by
Amer Zeidan, MBBS

0:55
Frontline Promise With Ziftomenib Combo in AML
3 months ago
by
Amer Zeidan, MBBS

0:42
Why Young Doctors Can't Forget the Basics
3 months ago
by
Yan Ji, MD

0:41
Is Over-Treatment the Hidden Problem in Modern Cancer Care?
3 months ago
by
Bruna Pellini, MD

0:20
Dr Pellini Busts Lung Cancer Myths
3 months ago
by
Bruna Pellini, MD

1:29
How to Use AI to Keep Up With 350,000+ Medical Papers
3 months ago
by
Pallav K. Mehta, MD

0:39
Advancing Innovation Through Community Oncology Care
3 months ago
by
Fran Gregory, PharmD, MBA

0:25
Why Women's Cancer Symptoms are Ignored
3 months ago
by
Narjust Florez, MD
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC
2
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
3
NDA Submission Initiated for Zipalertinib Combo in EGFR Exon 20+ NSCLC
4
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
5
